425: BioNTech to Acquire CureVac, Bolstering mRNA Oncology Pipeline and Manufacturing Capabilities

BioNTech SE has announced a definitive Purchase Agreement to acquire all shares of CureVac N.V., a strategic move aimed at strengthening its mRNA-based cancer immunotherapy programs and integrating CureVac's research and manufacturing site.

Summary

• BioNTech SE has entered into a definitive Purchase Agreement to acquire all shares of CureVac N.V.
• The acquisition is a key milestone in BioNTech's oncology strategy, focusing on pan-tumor programs, mRNA-based cancer immunotherapy candidates, and BNT327.
• This transaction follows BioNTech's recent partnership with Bristol Myers Squibb (BMS) to co-develop and co-commercialize BNT327.
• The acquisition is expected to close in 2025, after which CureVac will become a wholly-owned subsidiary of BioNTech.
• BioNTech plans to integrate CureVac's state-of-the-art research and manufacturing site in Tübingen as part of a group-wide transformation.
• An integration plan will be finalized and implemented after the successful closing of the transaction.

Sentiment

Score: 7

Explanation: The announcement is strategically positive for BioNTech, aiming to strengthen its oncology pipeline and capabilities. However, it is a forward-looking statement with significant inherent risks associated with M&A transactions, regulatory approvals, and integration, as detailed in the cautionary statements.

Positives

• Strengthens BioNTech's position in mRNA-based cancer immunotherapies, aligning with its core oncology strategy.
• Complements BioNTech's existing capabilities and proprietary technologies in mRNA design, delivery formulations, and manufacturing.
• Aims to advance the development of innovative and transformative cancer treatments and establish new standards of care.
• Integration of CureVac's state-of-the-art research and manufacturing site in Tübingen enhances BioNTech's operational footprint and capabilities.

Risks

• Uncertainties regarding the timing of the exchange offer and subsequent corporate reorganization of CureVac.
• Uncertainties as to how many of CureVac's shareholders will tender their shares in the exchange offer.
• Risk that competing offers or acquisition proposals for CureVac may be made.
• Possibility that various conditions to the consummation of the exchange offer and the transactions may not be satisfied or waived.
• Possibility of a termination of the Purchase Agreement.
• Ability to obtain necessary regulatory approvals on acceptable terms or within expected timing.
• Effects of disruption from the transactions and the impact of the announcement and pendency on BioNTech's and/or CureVac's business, including relationships with employees, business partners, or governmental entities.
• Risk that the exchange offer or other transactions may be more expensive to complete than anticipated.
• Risk that litigation in connection with the exchange offer or other transactions may result in significant costs of defense, indemnification, and liability.
• Diversion of management's attention from ongoing business operations and opportunities.
• General industry conditions and competition, including political, economic, and business conditions (interest rates, inflation, tariffs, currency exchange rates, ongoing conflicts).
• Impact of regulatory developments and changes in the United States, Europe, and other countries, including tax matters.
• Impact of pharmaceutical industry regulation and health care legislation.
• Particular prescribing preferences of physicians and patients.
• Competition from other products.
• Challenges and uncertainties inherent in new product development.
• Ability to obtain or maintain proprietary intellectual property protection.
• Safety, quality, data integrity, or manufacturing issues.
• Potential or actual data security and data privacy breaches.
• Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment.

Future Outlook

BioNTech anticipates that the acquisition of CureVac will strengthen its position in mRNA-based cancer immunotherapies, complementing its existing capabilities and proprietary technologies. The goal is to advance the development of innovative cancer treatments and establish new standards of care in the coming years. The transaction is expected to close in 2025, followed by the integration of CureVac's operations and the Tübingen site.

Management Comments

• "This transaction marks the next key milestone in the execution of our oncology strategy which focuses on two pan-tumor programs, mRNA-based cancer immunotherapy candidates and BNT327."
• "We see this strategic transaction as an investment in the future of cancer medicine by complementing BioNTechs capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing."
• "The goal is to advance the development of innovative and transformative cancer treatments and establish new standards of care for various types of cancer in the coming years."
• "We will develop an integration plan in alignment with our ongoing group-wide transformation, which we intend to finalize and implement after a successful closing of the transaction."
• "As part of this plan, we will integrate CureVacs state-of-the-art research and manufacturing site in Tbingen."

Industry Context

This acquisition reflects a trend of consolidation and strategic expansion within the biotechnology and pharmaceutical sectors, particularly in the rapidly evolving field of mRNA technology. BioNTech, a leader in mRNA-based vaccines, is leveraging this technology to expand its oncology pipeline, indicating a broader industry shift towards advanced therapeutic modalities for cancer treatment. The move also highlights the importance of integrating research, development, and manufacturing capabilities to accelerate drug discovery and commercialization.

Stakeholder Impact

• **Shareholders (CureVac):** Will be offered BioNTech ADSs in exchange for their shares, subject to the exchange offer and regulatory filings.
• **Shareholders (BioNTech):** Potential for long-term growth and strategic expansion in oncology, but also potential for dilution from ADS issuance and integration risks.
• **Employees (CureVac & BioNTech):** Subject to integration planning, which will determine impacts on site network and roles.
• **Business Partners:** Potential for changes in relationships due to the acquisition and integration.
• **Customers/Patients:** Potential for accelerated development of innovative cancer treatments, leading to new standards of care.

Next Steps

• BioNTech to hold a townhall on Monday, June 16, 3 pm CET, to provide more details and answer questions.
• BioNTech intends to file a Registration Statement on Form F-4 with the SEC, including an offer to exchange/prospectus.
• BioNTech intends to file a Tender Offer Statement on Schedule TO with the SEC.
• CureVac intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the exchange offer.
• Commencement of the exchange offer for CureVac's common shares.
• Finalization and implementation of an integration plan after the transaction closes.
• Integration of CureVac's Tübingen research and manufacturing site.

Key Dates

Keywords

BioNTech, CureVac, Acquisition, Merger, Oncology, mRNA, Cancer Immunotherapy, Biotechnology, Pharmaceuticals, BNT327, Tübingen, SEC Filing